Stem cell therapy for PBC not responding to standard treatment
Part of Digestive system clinical trials.
This study tests a new treatment using stem cells from umbilical cord blood to help people with primary biliary cholangitis (PBC) who haven't gotten better with standard medication. It aims to improve liver function and reduce symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You need a confirmed diagnosis of primary biliary cholangitis (PBC).
- You must have been taking ursodeoxycholic acid (UDCA) for at least 6 months without enough improvement.
- Your alkaline phosphatase (ALP) level must be elevated (at least 1.67 times the upper limit of normal but less than 10 times that limit).
- You cannot have other liver diseases (like hepatitis B or C) or complications like ascites or bleeding.
- You must not have had cancer in the past 2 years, except for certain minor skin conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at whether slowly reducing UDCA (a medication for primary biliary cholangitis) is safe and still helpful in people whose liver tests have improved. It may help some patients avoid higher doses if their disease is well controlled.
This trial studies whether fenofibrate (a cholesterol medicine) can improve outcomes in people with primary biliary cholangitis (PBC) who already take ursodeoxycholic acid (UDCA) but still have abnormal liver blood tests. It specifically looks at people with “compensated” (stable) cirrhosis—meaning the liver disease is present but not causing severe complications right now.
This trial tests an experimental drug (CS0159) for people with primary biliary cholangitis (PBC) who either didn't respond well to or couldn't take the standard treatment UDCA. It aims to improve liver function and reduce symptoms.
This research study tracks how well Primary Biliary Cholangitis (PBC) responds to standard medication (UDCA) and what happens to patients' health over time. It may help doctors understand which treatments work best for different people.
This trial tests a combination of two experimental drugs (seladelpar and cilofexor) for people with primary biliary cholangitis (PBC) who have not responded well to standard treatment. The goal is to see if these drugs can improve liver health and reduce symptoms.
This study looks at how well two medicines, ursodiol and seladelpar, work together for people with primary biliary cholangitis (PBC), a liver disease. It may help doctors understand the best way to treat PBC and improve liver health.
Hear when a new Primary Biliary Cholangitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.